About This Fund
Forbion Ventures Fund VI is a €750 million early-stage life sciences fund managed by Forbion, the Netherlands-based specialist venture capital firm headquartered in Naarden with offices in Munich and Boston. The fund closed at its hard cap in April 2023 as part of a simultaneous €1.35 billion raise alongside Forbion Growth Opportunities Fund II, the largest combined close in Forbion's history at that time. Returning investors scaled their commitments and were joined by new institutional allocators including the Scott Trust Endowment, Pictet Alternative Advisors, Loyola University of Chicago, and Dutch pension funds PME and PMT.
Forbion Ventures Fund VI is designed to build a diversified portfolio of innovative therapeutics-focused biotech companies, spanning both existing companies and newly created ventures co-founded by Forbion around assets sourced from pharmaceutical companies or academic institutions. This company-building approach—where Forbion actively contributes to the formation and early governance of portfolio companies—distinguishes the Ventures strategy from conventional early-stage VC. The fund targets approximately 15 companies across oncology, rare diseases, immunology, and high-impact therapeutic areas, primarily in Europe with selective North American exposure.
The fund continues the lineage of Forbion's flagship early-stage program, which has built a portfolio of over 40 companies including Beacon Therapeutics, Azafaros, AIRNA, Amphista Therapeutics, AM-Pharma, CatalYm, and Citryll. Predecessor vehicles have produced multiple successful exits and IPOs, establishing Forbion as one of Europe's most active and respected early-stage life sciences venture investors. The fund's company-building thesis positions it at the intersection of scientific innovation and commercial biotech development.